CAMBRIDGE, Mass.--(BUSINESS WIRE)--March 12, 2008--Sirtris
Pharmaceuticals, Inc. (NASDAQ: SIRT) today announces a license
agreement with Bayer CropScience AG, headquartered in Monheim, Germany
that grants exclusive, worldwide rights in the field of plants to a
certain Sirtris technology that contributes to cellular life span
extension and stress resistance. In return, Sirtris will receive an
initial up-front and future success bound milestone payments. Further
financial terms were not disclosed.
Crop damage from drought, lack of nutrients and other
environmental stresses is of growing worldwide concern. The licensed
technology provides possible new approaches to improving agricultural
"Sirtris has and continues to build a strong intellectual property
estate around the cellular pathways and distinct molecules associated
with longevity and diseases of aging," said Karl Normington, PhD,
Senior Director of Intellectual Property. "Sublicensing portions of
our technology to areas that are outside our principle lines of focus,
such as agricultural productivity, extend the applications of our
"We are pleased to be working with Bayer CropScience," said
Sirtris Pharmaceuticals Chief Executive Officer and Vice Chair
Christoph Westphal, MD, PhD. "Because of their focus on improving
agricultural productivity, they are well-positioned to leverage this
important technology for crop yield stability."
Michiel van Lookeren Campagne, PhD, Head of BioScience Research
for Bayer CropScience welcomes the partnership with Sirtris
Pharmaceuticals. "Global population growth and climate change have put
huge pressure on increasing agricultural productivity under
sub-optimal growing conditions. The integration of Sirtris'
proprietary technology into our seeds and traits R&D pipeline will
complement our activities in obtaining higher yielding crops -
especially under difficult climatic conditions."
About Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals is a biopharmaceutical company focused on
discovering and developing proprietary, orally available, small
molecule drugs with the potential to treat diseases associated with
aging, including metabolic diseases such as Type 2 Diabetes. Our drug
candidates are designed to mimic certain beneficial health effects of
calorie restriction, without requiring a change in eating habits, by
activation of sirtuins, a recently discovered class of enzymes that
the Company believes control the aging process. The company's
headquarters are in Cambridge, Massachusetts. This and further
information is available at: www.sirtrispharma.com
Forward Looking Statement
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Such
statements include, but are not limited to, the potential therapeutic
effects of SIRT1 activators; the progress and results of pre-clinical
and clinical studies of SIRT1 activators; the potential of Sirtris'
technology to improve agricultural productivity; the strength of the
Company's intellectual property estate; and the potential of sirtuin
modulators to receive regulatory approval. These forward-looking
statements about future expectations, plans and prospects of Sirtris
Pharmaceuticals involve significant risks, uncertainties and
assumptions, including risks related to the lack of results that would
provide a basis for predicting whether any of the Company's product
candidates will be safe or effective, or receive regulatory approval,
the possibility that results of pre-clinical studies are not
necessarily predictive of clinical trial results, the Company's
potential inability to initiate and complete pre-clinical studies and
clinical trials for its product candidates, the fact that none of the
Company's product candidates has received regulatory approvals, the
potential inability of the Company to gain market acceptance of the
Company's product candidates, and those other risks factors that can
be found in the Company's filings with the Securities and Exchange
Commission. Actual results may differ materially from those Sirtris
Pharmaceuticals contemplated by these forward-looking statements.
Sirtris Pharmaceuticals does not undertake to update any of these
forward-looking statements to reflect a change in its views or events
or circumstances that occur after the date of this release.
Sirtris Pharmaceuticals, Inc.
John Lacey, 617-252-6920
Associate Director of Corporate Communications
Bayer CropScience AG, Monheim, Germany
Utz Klages, +49 2173 38-3125
SOURCE: Sirtris Pharmaceuticals, Inc.